FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	ourden								
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Renger John (Last) (First) (Middle) C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200						Date /05/2	of Earl	iest Tran	saction	(Mon	th/E	ymbol ngs, Ind Day/Year)	(Ch	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Scientific Officer 6. Individual or Joint/Group Filing (Check Applicable							
(Street) CAMBR (City)			02141 (Zip)		-											Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)							2A. Deemed Execution Date, if any (Month/Day/Year		Code (Inst				ties Acquired (A) I Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F Reporte	es ally Following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Co	de V	,	Amount		(A) or (D)	Price	Transaci (Instr. 3	tion(s)			(111541. 4)			
Common Stock 08/0						2			М	(1)		20,000	0	A	\$3.5	22	,704		D		
Common Stock 08/05						2			S	1)		20,000	0	D	\$32	5 2,	704		D		
Common Stock 08/08/					3/2022	2				(1)		10,000	0	A \$3.		12,704		D			
Common	Stock			08/08	3/2022	2			S	1)		10,000	0	D	\$37.7	5 2,	704	D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date, 1	4. Transactior Code (Instr. 8)				6. Date Exercise Expiration Date (Month/Day/Yea				of Se Unde Deriv	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable		xpiration ate	Title		Amount or Number of Shares						
Stock Option (Right to Buy)	\$3.5	08/05/2022		1	M ⁽¹⁾			20,000	(2)	0	4/02/2029	Com		20,000	\$0.00	119,77	70	D		
Stock					Ī																

Explanation of Responses:

\$3.5

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.

 $M^{(1)}$

2. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

(Right to Buy)

> /s/ Mark Bodenrader, as Attorney-in-Fact 08/09/2022

10,000

Stock

\$0.00

109,770

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

08/08/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

10,000

(2)

04/02/2029